Scholarlink

<p>In the first episode of our podcast series, we introduce the emerging landscape of <i>HER2</i>-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. We explain what makes <i>HER2</i>-mutant NSCLC unique, from its epidemiology and biology to the molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in NSCLC, the role of HER2 as a therapeutic target, and how advances in molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of <i>HER2</i>-mutant NSCLC and the evolving therapeutic landscape that is reshaping management strategies for this aggressive disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Vivek Subbiah,
  • Martin Dietrich,
  • Xiuning Le

摘要

In the first episode of our podcast series, we introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. We explain what makes HER2-mutant NSCLC unique, from its epidemiology and biology to the molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in NSCLC, the role of HER2 as a therapeutic target, and how advances in molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of HER2-mutant NSCLC and the evolving therapeutic landscape that is reshaping management strategies for this aggressive disease.